-
Mashup Score: 0Oncology Best Practice Grand Rounds Series: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer and What You Need to Know - 7 month(s) ago
null
Source: www.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Cross Q&A: Evaluating Ponatinib and Asciminib as 3L Therapy in CML - 7 month(s) ago
Considerations for selecting between ponatinib and asciminib as third-line therapies for CML based on factors such as disease burden, mutations, and patient tolerability.
Source: www.cancernetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Oncology Best Practice Grand Rounds Series: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer and What You Need to Know - 7 month(s) ago
null
Source: www.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During a Targeted Oncology™ Case-Based Roundtable™ event, Kendra Sweet, MD, and participants discussed dosing and toxicity concerns with tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Episode 5: Monitoring and Diagnostics in Chronic Myeloid Leukemia - 7 month(s) ago
Drs Michael J. Mauro and Jerald P. Radich discuss monitoring and diagnostics in chronic myeloid leukemia, including the Philadelphia chromosome and how it plays into the current treatment of CML.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Bosutinib Is Approved for Pediatric Ph+ CP–Chronic Myeloid Leukemia - 7 month(s) ago
The FDA has approved bosutinib to treat pediatric patients with Philadelphia chromosome–positive, chronic-phase chronic myelogenous leukemia.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Optimizing Ponatinib in CML: Understanding AOEs in the PACE Trial - 8 month(s) ago
A retrospective analysis of arterial occlusive events in the PACE trial, shedding light on risk factors and management strategies for ponatinib treatment in CML patients.
Source: www.cancernetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
The BCR::ABL1 gene fusion initiates chronic myeloid leukemia (CML); however, evidence has accumulated from studies of highly selected cohorts that variants in other cancer-related genes are associated with treatment failure. Nevertheless, the true incidence and impact of additional genetic abnormalities (AGA) at diagnosis of chronic phase (CP)-CML is unknown. We sought to determine whether AGA at diagnosis in a consecutive imatinib-treated cohort of 210 patients enrolled in the TIDEL-II trial influenced outcome despite a highly proactive treatment intervention strategy. Survival outcomes including overall survival, progression-free survival, failure-free survival, and BCR::ABL1 kinase domain mutation acquisition were evaluated. Molecular outcomes were measured at a central laboratory and included major molecular response (MMR, BCR::ABL1 ≤0.1%IS), MR4 (BCR::ABL1 ≤0.01%IS), and MR4.5 (BCR::ABL1 ≤0.0032%IS). AGA included variants in known cancer genes and novel rearrangements involving th
Source: haematologica.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Genomics, Goals Drive TKI Selection for CML - 8 month(s) ago
There are several options the frontline setting for patients with chronic phase CML, with major randomized phase 3 trials showing long-term results for second-generation tyrosine kinase inhibitors.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Nilotinib Linked to Metabolic Syndrome and CVD in CML - 8 month(s) ago
Investigators suggest using other TKIs in patients with preexisting diabetes and hyperlipidemia.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet
You don’t want to miss PER’s Oncology Best Practice on CML happening October 11th! Register today to hear Elias Jabbour, MD, and other experts discuss management strategies for patients undergoing TKI therapy for CML. https://t.co/UvXrsAKWn9 #CML #hematology #gotoPER https://t.co/hrjy9kvtEL